Every 10-Q that PAVmed Inc. (PAVM) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow PAVM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PAVM filings page.
PAVmed Inc. reported minimal revenue and continued losses for the six months ended June 30, 2026 while relying heavily on financing transactions. Revenue was only $55,000 for the period, against operating expenses of $15.1 million, leading to an operating loss of $15.1 million and a net loss attributable to common stockholders of $12.5 million. Operating cash outflow was $5.3 million, leaving cash of $3.8 million and total assets of $40.2 million, most of which is the $33.5 million equity-method stake in Lucid Diagnostics.
The company completed a $30 million Series D preferred financing in February 2026, all of which converted into 4,615,393 common shares after shareholder approval, and issued a new $15.0 million Senior Secured Convertible Note due 2029 with a 15.0% coupon and tight covenants, including minimum cash and Lucid value tests. Legacy Series C preferred stock and the prior September 2022 note were redeemed or refinanced, generating a $3.4 million debt extinguishment loss and a $6.7 million deemed dividend. Management explicitly states that recurring losses, limited cash, small working capital of about $0.8 million, and dependence on raising additional capital and growing Veris revenue raise substantial doubt about PAVmed’s ability to continue as a going concern within one year of the report date.
PAVmed Inc. reported first-quarter 2026 results showing minimal revenue and ongoing losses while relying heavily on financing transactions. Revenue for the three months ended March 31, 2026 was $22,000, against operating expenses of $8.1 million, leading to an operating loss of $8.0 million. After fair value gains on investments and debt and a large deemed dividend on preferred stock, net loss attributable to common stockholders was about $7.0 million, or $(4.42) per basic and diluted share.
To strengthen liquidity, PAVmed issued $30 million of Series D Convertible Preferred Stock and a new $15.0 million senior secured convertible note, refinanced prior convertible debt, redeemed its Series C preferred stock, and converted the Series D into 4,615,393 common shares. Cash increased to $6.5 million at March 31, 2026 from $1.5 million at year-end, and working capital was approximately $3.8 million. However, management disclosed that recurring losses, low revenues and dependence on additional capital raise substantial doubt about the company’s ability to continue as a going concern over the next year.
PAVmed Inc. filed its Q3 2025 10‑Q, reporting very limited operating revenue and a continued focus on restructuring its capital base while relying on related‑party service income. Revenue was $5 thousand for the quarter and $19 thousand year‑to‑date, reflecting the shift away from consolidated Lucid Diagnostics revenue and toward Veris Cancer Care Platform subscriptions.
The company posted a Q3 operating loss of $4.8 million and a net loss attributable to common stockholders of $6.3 million. Year‑to‑date net loss attributable to common stockholders was $1.9 million. Cash was $3.1 million and current liabilities included $6.9 million of Senior Secured Convertible Notes at fair value. Management disclosed “substantial doubt” about the company’s ability to continue as a going concern, citing low revenues, operating losses, and liquidity needs.
Total assets were $38.1 million, including a $31.6 million equity‑method investment in Lucid Diagnostics measured at fair value. The quarter included a $4.4 million unrealized loss on that investment and $3.15 million of management fee income under the Lucid Management Services Agreement. Total stockholders’ equity was $22.5 million, aided by preferred equity activity and capital raises. Shares outstanding were 25,086,881 as of September 30, 2025 and 29,671,925 as of November 7, 2025.